Scilex Holding Co

Scilex Holding Company (Nasdaq: SCLX) is a commercial-stage specialty pharmaceutical company focused on non-opioid pain management therapeutics that entered the public markets in December 2022 through a de-SPAC merger with Vickers Vantage Corp. I, a blank-check vehicle sponsored by Vickers Financial Group that completed its IPO in 2021. The company markets approved products including ZTlido and GLOPERBA and operates within the specialty pharma and pain management sector. Scilex filed an 8-K current report with the SEC on June 24, 2026, reflecting its ongoing public reporting obligations as a post-merger listed company. Sign up for SpacDesk to access the full filing history, sponsor profile, and deal analytics for SCLX.